|
|
|
|
Generic Names of Some Trade Name Drugs, THE MERCK MANUAL OF HEALTH & AGING
Committed to Providing Medical Information Table of Contents Index Enlarge Text Reset Text Shrink Text -- Buy the Book Learn about participating in clinical trials at this government website: www.clinicaltrials.gov - APPENDIX I - Drug Names: Generic and Trade TOPICS - Introduction -~ Some Trade Names of Generic Drugs -~ Generic Names of Some Trade Name Drugs - Generic Names of Some...
|
|
|
Some Trade Names of Generic Drugs, THE MERCK MANUAL OF HEALTH & AGING
Committed to Providing Medical Information Table of Contents Index Enlarge Text Reset Text Shrink Text -- Buy the Book Learn about participating in clinical trials at this government website: www.clinicaltrials.gov - APPENDIX I - Drug Names: Generic and Trade TOPICS - Introduction -~ Some Trade Names of Generic Drugs-~ Generic Names of Some Trade Name Drugs - Some Trade Names of...
|
|
|
http://www.novartis.com/downloads_new/investors/2005_Q3_press_release_corrected.pdf
Investor Relations Novartis International AG CH- 4002 Basel Switzerland Novartis Corporation 608 Fifth Avenue New York, NY 10020 USA (1) Pro forma basis: This report reflects the adoption of new IFRS accounting standards that became effective on January 1, 2005, and other presentational changes.
In the US, third- quarter sales advanced 11% to USD 2.1 billion as strong performances...
duplicates:
http://www.novartis.com/downloads_new/investors/2005_Q3_press_release_corrected.pdf
|
|
|
http://www.novartis.com/downloads_new/investors/Conference_UBS_Epstein_September_27_2005.pdf
Leading Innovations David R.
Such statements include descriptions of the Company's investment and research and development programs and anticipated expenditures in connection therewith; descriptions of new products or new indications for existing products expected to be introduced by the Company and anticipated customer demand for such products and for products in the Company's...
duplicates:
http://www.novartis.com/downloads_new/investors/Conference_UBS_Epstein_September_27_2005.pdf
|
|
|
Microsoft PowerPoint - 09_Reinhardt_final_Print.ppt
1 New Therapies for Highly Prevalent Diseases Joerg Reinhardt Head of Pharma Development Novartis Pharma AG 2 London Pharmaceutical Pipeline Event 2005 / Joerg Reinhardt 2005 Is a Successful Year for Novartis ° Exjade ® Phase III !
° LDT600 Phase III (!) ° Femara ® BIG 1-98 !
° Femara ® early adjuvant breast cancer !
placebo: p=0.007 FTY720...
author: MEETIPL1
duplicates:
http://www.novartis.com/downloads/09_Reinhardt_final_print_london.pdf
http://www.novartis.com/downloads_new/investors/09_Reinhardt_final_print_london.pdf
http://www.novartis.com/downloads/09_Reinhardt_final_print_london.pdf
|
|
|
e_s01_s52_FF12
FACTS & FIGURES 2005 CARING AND CURING ©Novartis AG, July 2005.
Decades of experience and know- how make Sandoz a renowned partner in pharmaceuticals, biogenerics, and anti- infectives.
novartis.
Chairman and CEO Urs Baerlocher, J.
Singh Finance & Administration Thomas van Laar Technical Operations BUSINESS UNIT HEADS David Epstein Specialty Medicines and Oncology...
duplicates:
http://www.novartis.com/downloads/Nov_F_F05_E.pdf
|
|
|
Nov.F&F04_E_12.qxd
FACTS & FIGURES 2004/ 2005 CARING AND CURING 1 OUR MISSION We want to discover, develop and successfully market innovative products to cure diseases, to ease suffering and to enhance the quality of life.
CONSUMER HEALTH The Consumer Health Division focuses on creating, developing and manufacturing a wide range of competitively differentiated products that restore, maintain or...
author: comfactory
duplicates:
http://www.novartis.com/downloads/Nov_F_F04_E.pdf
|
|
|
http://www.novartis.com/downloads_new/investors/fresco_analysts_presentation%20_01_2005/03%20FRESCO%202004%20David%20Epstein%202005-01-20_modified%2018_03_05%20Analysts.pdf
1 Novartis Oncology and Specialty Medicines David R.
BMS354825 Different Approaches to Treating CML · AMN107: the most selective BCR- ABL inhibitor reported to date · We believe this selectivity will confer best- in- class tolerability critical for a long- term therapy in CML AMN107 BMS354825 Pre- clinical activity against most BCR- ABL mutants Activity against T315I...
duplicates:
http://www.novartis.com/downloads_new/investors/fresco_analysts_presentation%20_01_2005/03%20FRESCO%202004%20David%20Epstein%202005-01-20_modified%2018_03_05%20Analysts.pdf
http://www.novartis.com/downloads_new/investors/fresco_analysts_presentation%20_01_2005/03%20FRESCO%202004%20David%20Epstein%202005-01-20_modified%2018_03_05%20Analysts.pdf
|
|
|
http://www.novartis.com/downloads_new/investors/fresco_analysts_presentation%20_01_2005/03%20FRESCO%202004%20David%20Epstein%202005-01-20_modified%2018_03_05%20Analysts.pdf page 9
duplicates:
http://www.novartis.com/downloads_new/investors/fresco_analysts_presentation%20_01_2005/03%20FRESCO%202004%20David%20Epstein%202005-01-20_modified%2018_03_05%20Analysts.pdf
http://www.novartis.com/downloads_new/investors/fresco_analysts_presentation%20_01_2005/03%20FRESCO%202004%20David%20Epstein%202005-01-20_modified%2018_03_05%20Analysts.pdf
http://www.novartis.com/downloads_new/investors/fresco_analysts_presentation%20_01_2005/03%20FRESCO%202004%20David%20Epstein%202005-01-20_modified%2018_03_05%20Analysts.pdf
http://www.novartis.com/downloads_new/investors/fresco_analysts_presentation%20_01_2005/03%20FRESCO%202004%20David%20Epstein%202005-01-20%20Analysts_Corrected_27_01_2005.pdf
|
|
|
http://www.novartis.com/downloads_new/investors/fresco_analysts_presentation%20_01_2005/03%20FRESCO%202004%20David%20Epstein%202005-01-20%20Analysts_Corrected_27_01_2005.pdf
Conte, oral presentation, ESMO 2004 Comparison of major bisphosphonates 2 18 FRESCO 2004 / David Epstein / 2005- 01- 20 / Analysts Recent Japanese Zometa ® Data Reinforces Efficacy of Zometa ® 29.8 49.6 0 10 20 30 40 50 60 % of patients P = .003 Significantly fewer breast cancer patients (39.9% relative reduction) experienced an SRE 1 with Zoledronic ...
|
|
|
Microsoft PowerPoint - ING presentation Final print.ppt
1 Sustained High Performance Karen J.
The information presented in this handout represents management's expectations and intentions as of December 7th, 2004.
Competitors Average Quality Rating (Normalized) Novartis Index Competition Index (bar = top rated competitor) 100 = average in each Country USA 1 Japan 1 Ger- many 2 France 2 Italy 2 UK 2 Spain 2 Switzer- land 2 Brazil 1...
author: luedisu1
duplicates:
http://www.novartis.com/downloads_new/investors/Final%20print%20presentation%20ING.pdf
|
|
|
Microsoft PowerPoint - ING presentation Final print.ppt page 21
author: luedisu1
duplicates:
http://www.novartis.com/downloads_new/investors/Final%20print%20presentation%20ING.pdf
|
|
|
Database Z
Z - investigational drugs, therapies and vaccines # - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z From this page you may order documents with information covering investigational products To purchase documents on-line click on- -link attached to selected document!- The fee is $15 per document Documents are delivered by e-mail...
|
|
|
http://www.novartis.com/downloads_new/investors/Lombard_Odier_presentation_for_print.pdf
Lombard Odier Conference 5 May, 2004 Raymund Breu CFO, Novartis AG The following information contains certain "Forward- looking Statements" relating to the Company's business, which can be identified by the use of forward- looking terminology such as "will" or "expect", or by discussions of strategy, plans, intentions or potential outcomes.
Should one or more of these risks or...
duplicates:
http://www.novartis.com/downloads_new/investors/Lombard_Odier_presentation_for_print.pdf
|
|
|
Outperforming the competition
Sabine Moravi-Bottoli Outperforming the competition Sabine Moravi _ _ Source Germo H.
Such statements reflect the current views of the Company with respect to future events and are subject to certain risks, uncertainties and assumptions.
Many factors could cause the actual results, performance or achievements of the Company to be materially different from any future results,...
author: Sabine Moravi
duplicates:
http://www.novartis.com/downloads/Novartis%20David%20Epstein%20FINAL%20March%2010%202004.ppt
|
|
|
Outperforming the competition
Sabine Moravi-Bottoli Outperforming the competition Sabine Moravi Source Germo H.
Such statements include descriptions of the Company's investment and research and development programs and anticipated expenditures in connection therewith; descriptions of new products or new indications for existing products expected to be introduced by the Company and anticipated customer demand...
author: Sabine Moravi
duplicates:
http://www.novartis.com/downloads_new/investors/FINAL%20Novartis%20M%20Hukkelhoven%20at%20Lehman%20Brothers%20March%204%202004.ppt
|
|
|
What is New
Folic acid, 350 to 1000 micrograms orally, was given daily, beginning 1 to 3 weeks prior to the first chemotherapy dose and continued daily for 1 to 3 weeks after treatment discontinuation
Full prescribing information, including clinical trial information, safety, dosing, drug-drug interactions and contraindications is available at: http://www.fda.gov/cder/foi/label/2002...
author: Steve Hirschfeld
|
|
|
http://www.fda.gov/cder/orange/appendix_a.txt
4, ACETAMINOPHEN TYLENOL W/ CODEINE, ACETAMINOPHEN TYLENOL, ACETAMINOPHEN (OTC) TYLOX, ACETAMINOPHEN TYLOX-325, ACETAMINOPHEN TYMTRAN, CERULETIDE DIETHYLAMINE TYZINE, TETRAHYDROZOLINE HYDROCHLORIDE TZ-3, TIOCONAZOLE (OTC) ** U ** U-CORT, HYDROCORTISONE ACETATE U-GENCIN, GENTAMICIN SULFATE UCEPHAN, SODIUM BENZOATE ULO, CHLOPHEDIANOL HYDROCHLORIDE ULTANE, SEVOFLURANE ULTIVA,...
|
|
|
Microsoft PowerPoint - FRESCO 2003 Joerg Reinhardt 2004-01-21 Analysts print.ppt
1 Development Pipeline Delivering Top Performance Joerg Reinhardt Head of Pharma Development, Novartis Pharma AG 2 FRESCO 2003 / Joerg Reinhardt / 2004-01-22 / Analysts Agenda ° Update on clinical profile of key projects ° Recent additions further strengthen the pipeline ° Conclusion 2 3 FRESCO 2003 / Joerg Reinhardt / 2004-01-22 / Analysts A Focused Portfolio in...
author: releano1
duplicates:
http://www.novartis.com/downloads_new/investors/Reinhardt_Analyst_Web.pdf
|
|
|
Microsoft PowerPoint - FRESCO 2003 Thomas Ebeling 2004-01-21 Analysts print.ppt
1 Pharmaceuticals Outperforming the Competition Thomas Ebeling CEO, Novartis Pharma AG 2 FRESCO 2003 / Thomas Ebeling / 2004-01-22 / Analysts Summary ° Fastest organic growth among top 10 companies ° Operating Income margin slightly reduced Š Significant R&D; investments Š Challenging pricing environment ° Industry leading pipeline ° Strong short- and...
author: releano1
duplicates:
http://www.novartis.com/downloads_new/investors/Ebeling_Analyst_web.pdf
|
|
|
Microsoft PowerPoint - FRESCO 2003 Daniel Vasella Start 2004-01-22 Analysts print.ppt
1 Highlights 2003 Daniel Vasella, MD Chairman and CEO, Novartis AG 2 FRESCO 2003 / Daniel Vasella / 2004-01-22 / Analysts In USD m 2003 2002 Change Change in % USD in % LC Sales 24 864 20 877 +19 +11 Operating income 5 889 5 092 +16 as a % of sales 23.7 24.4 Net income 5 016 4 725 +6 as a % of sales 20.2 22.6 Free Cash Flow 3 628 2 958 +23 as a % of sales 14.6 14.2 EPS (USD) 2.03 1...
author: releano1
duplicates:
http://www.novartis.com/downloads_new/investors/Vasella_Analyst_Start_web.pdf
|
|
|
Microsoft PowerPoint - FRESCO 2003_Thomas Ebeling_2004-01-21 Media Print.ppt
8 15 FRESCO 2003 / Thomas Ebeling / 2004-01-22 / Media Key Anticipated Events 2004 Data Submissions Anticipated approvals ° Diovan ® VALUE ° Femara ® BIG ° Prexige ® TARGET ° Diovan ® VALIANT (EU) ° Xolair ® (EU) ° Femara ® extended adjuvant ° Zoledronic acid in Paget’s disease ° Zelmac ® IBS...
author: releano1
|
|
|
Microsoft PowerPoint - FRESCO 2003_Thomas Ebeling_2004-01-21 Media Print.ppt page 8
author: releano1
|
|
|
21-223_Zometa.htm
Food and Drug Administration • Center for Drug Evaluation and Research Approval Package Search Zometa (Zoledronic Acid) Injection Company:--Novartis Pharmaceuticals Corp
Application No.:--21-223 Approval Date:-8/20/2001 - Approval Letter(s) - Printed Labeling - Medical Review(s) Part 1 - Part 2 - Chemistry Review(s) Pharmacology Review(s) - Part 1 - Part 2...
author: Paul Stauffer
|
|
|
../2002/21-386_Zometa
Food and Drug Administration • Center for Drug Evaluation and Research Title Search Zometa (Zoledronic Acid) Injection Company:--Novartis Pharmaceuticals Corporation Application No.:--21-386 Approval Date:-2/22/2002 Approval Letter(s) - Printed Labeling - Medical Review(s) Part 1 - Part 2 - Part 3 - Part 4 - Chemistry Review(s) - Environmental Assessment -...
author: USERNAME
|
